^
Association details:
Biomarker:TERT mutation
Cancer:Squamous Cell Carcinoma of Head and Neck
Drug Class:PD1 inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
Title:

685P - Genomic characteristics and immunotherapy outcomes in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)

Published date:
09/05/2022
Excerpt:
Interestingly, PIK3CA alteration was negatively correlated with OS (HR 1.99, P = 0.027), while TERT promoter mutation showed a positive correlation with OS (HR 0.44, P = 0.05)....Our single institution data with anti-PD-1 ICB Tx in R/M HNSCC is consistent with registration study results. The correlation between PIK3CA and TERT promoter gene alterations and ICB outcome warrants further investigation.